Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy.

Interdiscip Cardiovasc Thorac Surg · 2024 · PMC11681939 · PMID 39680899

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

showed a trendP = 0.076so close (0.05 < p ≤ 0.1)

Notably, within this subgroup, patients receiving ≥ 2 cycles of neoadjuvant immunochemotherapy showed a trend towards better overall survival ( P = 0.076) and disease-free survival ( P = 0.062).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.